» Articles » PMID: 37264485

Epidemiology and Risk Factors of 28-day Mortality of Hospital-acquired Bloodstream Infection in Turkish Intensive Care Units: a Prospective Observational Cohort Study

Abstract

Objectives: To uncover clinical epidemiology, microbiological characteristics and outcome determinants of hospital-acquired bloodstream infections (HA-BSIs) in Turkish ICU patients.

Methods: The EUROBACT II was a prospective observational multicontinental cohort study. We performed a subanalysis of patients from 24 Turkish ICUs included in this study. Risk factors for mortality were identified using multivariable Cox frailty models.

Results: Of 547 patients, 58.7% were male with a median [IQR] age of 68 [55-78]. Most frequent sources of HA-BSIs were intravascular catheter [182, (33.3%)] and lower respiratory tract [175, (32.0%)]. Among isolated pathogens (n = 599), 67.1% were Gram-negative, 21.5% Gram-positive and 11.2% due to fungi. Carbapenem resistance was present in 90.4% of Acinetobacter spp., 53.1% of Klebsiella spp. and 48.8% of Pseudomonas spp. In monobacterial Gram-negative HA-BSIs (n = 329), SOFA score (aHR 1.20, 95% CI 1.14-1.27), carbapenem resistance (aHR 2.46, 95% CI 1.58-3.84), previous myocardial infarction (aHR 1.86, 95% CI 1.12-3.08), COVID-19 admission diagnosis (aHR 2.95, 95% CI 1.25-6.95) and not achieving source control (aHR 2.02, 95% CI 1.15-3.54) were associated with mortality. However, availability of clinical pharmacists (aHR 0.23, 95% CI 0.06-0.90) and source control (aHR 0.46, 95% CI 0.28-0.77) were associated with survival. In monobacterial Gram-positive HA-BSIs (n = 93), SOFA score (aHR 1.29, 95% CI 1.17-1.43) and age (aHR 1.05, 95% CI 1.03-1.08) were associated with mortality, whereas source control (aHR 0.41, 95% CI 0.20-0.87) was associated with survival.

Conclusions: Considering high antimicrobial resistance rate, importance of source control and availability of clinical pharmacists, a multifaceted management programme should be adopted in Turkish ICUs.

Citing Articles

Demographics, epidemiology, mortality and difficult-to-treat resistance patterns of bacterial bloodstream infections in the global US Military Health System from 2010 to 2019: a retrospective cohort study.

Vostal A, Grance M, Powers 3rd J, Kadri S, Warner S, Chukwuma U BMJ Open. 2025; 15(3):e094861.

PMID: 40032367 PMC: 11877242. DOI: 10.1136/bmjopen-2024-094861.


Demographics, Epidemiology, Mortality, and Difficult-To-Treat Resistance Patterns of Bacterial Bloodstream Infections in the Global United States Military Health System from 2010-2019: A Retrospective Cohort Study.

Vostal A, Grance M, Powers J, Powers 3rd J, Kadri S, Warner S medRxiv. 2025; .

PMID: 39802776 PMC: 11722484. DOI: 10.1101/2024.10.02.24314780.


Bacterial co-infection in COVID-19: a call to stay vigilant.

Liu S, Yu C, Tu Q, Zhang Q, Fu Z, Huang Y PeerJ. 2024; 12:e18041.

PMID: 39308818 PMC: 11416760. DOI: 10.7717/peerj.18041.


Bloodstream infections in the era of the COVID-19 pandemic: Changing epidemiology of antimicrobial resistance in the intensive care unit.

Ntziora F, Giannitsioti E J Intensive Med. 2024; 4(3):269-280.

PMID: 39035613 PMC: 11258508. DOI: 10.1016/j.jointm.2023.12.004.

References
1.
. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

2.
Grasselli G, Scaravilli V, Mangioni D, Scudeller L, Alagna L, Bartoletti M . Hospital-Acquired Infections in Critically Ill Patients With COVID-19. Chest. 2021; 160(2):454-465. PMC: 8056844. DOI: 10.1016/j.chest.2021.04.002. View

3.
Isler B, Ozer B, Cinar G, Aslan A, Vatansever C, Falconer C . Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting. Eur J Clin Microbiol Infect Dis. 2022; 41(5):841-847. DOI: 10.1007/s10096-022-04425-4. View

4.
Van Heuverswyn J, Valik J, van der Werff S, Hedberg P, Giske C, Naucler P . Association Between Time to Appropriate Antimicrobial Treatment and 30-day Mortality in Patients With Bloodstream Infections: A Retrospective Cohort Study. Clin Infect Dis. 2022; 76(3):469-478. PMC: 9907509. DOI: 10.1093/cid/ciac727. View

5.
Timsit J, Ruppe E, Barbier F, Tabah A, Bassetti M . Bloodstream infections in critically ill patients: an expert statement. Intensive Care Med. 2020; 46(2):266-284. PMC: 7223992. DOI: 10.1007/s00134-020-05950-6. View